N/A
Manufactured by Fresenius Kabi USA, LLC
37,274 FDA adverse event reports analyzed
Last updated: 2026-04-14
VALPROATE SODIUM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Fresenius Kabi USA, LLC. The most commonly reported adverse reactions for VALPROATE SODIUM include DRUG INEFFECTIVE, DRUG INTERACTION, OFF LABEL USE, FOETAL EXPOSURE DURING PREGNANCY, SOMNOLENCE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for VALPROATE SODIUM.
Out of 19,782 classified reports for VALPROATE SODIUM:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 37,274 FDA FAERS reports that mention VALPROATE SODIUM. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, DRUG INTERACTION, OFF LABEL USE, FOETAL EXPOSURE DURING PREGNANCY, SOMNOLENCE, EPILEPSY. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Fresenius Kabi USA, LLC in connection with VALPROATE SODIUM. Always verify the specific product and NDC with your pharmacist.